I’m running for the Cystic Fibrosis Foundation because real cures require bold bets.

Cystic Fibrosis is caused by a single broken gene. The challenge is that this error looks different in different patients, which makes it hard to fix with a one-size-fits-all drug unless you can replace the complete gene. 

When I co-founded Kano Therapeutics, Cystic Fibrosis was immediately at the top of my list — because new DNA-based therapies could finally make something powerful possible: replacing the entire broken gene, not just patching parts of it. That means restoring function, regardless of which specific mutation a patient has.

The Cystic Fibrosis Foundation has consistently stepped in where risk is high but impact is transformative, supporting early-stage ideas and startups willing to think bigger.

That courage matters. Because when you pair a disease as well-understood as Cystic Fibrosis with an organization brave enough to fund the future, breakthroughs happen.

A durable gene therapy for Cystic Fibrosis patients will set the path for cures benefiting all patients with rare genetic diseases that currently cannot be addressed. 

Your support makes you my hero on every mile.